Third Harmonic Bio News

Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects

TipRanksAug 9 09:08 ET

Third Harmonic Bio Analyst Ratings

BenzingaAug 9 05:28 ET

Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20

BenzingaAug 9 05:28 ET

Buy Rating Justified by Third Harmonic Bio's Promising Drug THB335 and Swift Clinical Advancements

TipRanksAug 8 17:48 ET

Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)

TipRanksAug 8 10:54 ET

Third Harmonic Bio Analyst Ratings

BenzingaJun 18 05:15 ET

Third Harmonic Bio Analyst Ratings

BenzingaJun 7 05:24 ET

Analysts Are Bullish on Top Healthcare Stocks: Third Harmonic Bio, Inc. (THRD), Treace Medical Concepts (TMCI)

TipRanksNov 9, 2023 21:21 ET

Morgan Stanley Maintains Equal-Weight on Third Harmonic Bio, Raises Price Target to $7

BenzingaAug 11, 2023 09:16 ET

Third Harmonic Bio Analyst Ratings

BenzingaAug 11, 2023 09:15 ET

Analysts Offer Insights on Healthcare Companies: Third Harmonic Bio, Inc. (THRD) and Verve Therapeutics (VERV)

TipRanksAug 10, 2023 15:50 ET

LifeSci Capital Upgrades Third Harmonic Bio, Inc. (THRD) to a Buy

TipRanksJul 25, 2023 17:15 ET

LifeSci Capital Sticks to Its Hold Rating for Third Harmonic Bio, Inc. (THRD)

TipRanksMay 11, 2023 19:25 ET

LifeSci Capital Keeps Their Hold Rating on Third Harmonic Bio, Inc. (THRD)

TipRanksDec 19, 2022 11:30 ET

Third Harmonic Bio Analyst Ratings

Benzinga Analyst RatingsDec 16, 2022 06:03 ET

Jefferies Downgrades Third Harmonic Bio to Hold, Lowers Price Target to $3.6

Benzinga Real-time NewsDec 16, 2022 06:02 ET

Third Harmonic Bio, Inc. (THRD) Has a New Rating From Jefferies

TipRanksOct 10, 2022 12:50 ET

Morgan Stanley Starts Third Harmonic Bio at Overweight With $34 Price Target

MT NewswiresOct 10, 2022 07:08 ET

Third Harmonic Bio Analyst Ratings

Benzinga Analyst RatingsOct 10, 2022 06:14 ET